The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

SureCN64996     3-[(5-nitro-2- furyl)methylideneamino]- 1,3...

Synonyms: CAS-67-45-8, ZINC00113418, AC1NS4EQ, NCGC00016299-01
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of furazolidone


Psychiatry related information on furazolidone


High impact information on furazolidone

  • One-week-old turkey poults were fed furazolidone for 14 days to induce dilated cardiomyopathy [8].
  • The recovery of NF expression in good regenerators was independent of axon growth across the lesion, because excision of a segment of spinal cord caudal to the transection site blocked regeneration but did not prevent the return of NF-180 mRNA [9].
  • During the first 4 weeks after operation, NF message levels were reduced dramatically in all axotomized reticulospinal neurons, on the basis of semiquantitative in situ hybridization for the single lamprey NF subunit (NF-180) [9].
  • The pathways participating in the metabolism of the nitrofuran antimicrobial drug N-[5-nitro-2-furfurylidene]-3-amino-2-oxazolidinone (furazolidone) in intact cells were investigated in the human intestinal cell line Caco-2 [10].
  • The first reducing equivalent required for the formation of the nitroanion derivative of furazolidone appeared to be provided essentially by the microsomal cytochrome P450 reductase [10].

Chemical compound and disease context of furazolidone


Biological context of furazolidone


Anatomical context of furazolidone


Associations of furazolidone with other chemical compounds


Gene context of furazolidone


Analytical, diagnostic and therapeutic context of furazolidone

  • Detection of furazolidone in human biological fluids by high performance liquid chromatography [33].
  • HPLC is a rapid and sensitive method for the quantitation of furazolidone in biological fluids [33].
  • The two isolates with the highest ID50 values for furazolidone in vitro were from patients who had persistent symptoms after treatment with this drug; these patients subsequently responded to treatment with a nitroimidazole with greater in vitro potency [34].
  • After 19 new cases were detected early in the summer of 1985, oral administration of furazolidone throughout their entire hospital stay (2.5 mg/kg twice daily) was recommended for all subsequently hospitalized infants [35].
  • A control group of Broad Breasted White turkey poults was given regular feed without additive, whereas the experimental group was given the control ration with 700 ppm of furazolidone at 1 week of age for 3 weeks (DCM) [36].


  1. Furazolidone in peptic ulcer. Zhao, H.Y., Li, G.Z., Guo, J.D., Yan, Z., Sun, S.W., Li, L.S., Duan, Y.M., Yue, F.Z. Lancet (1985) [Pubmed]
  2. In-vitro sensitivity of Campylobacter pyloridis to furazolidone. Howden, A., Boswell, P., Tovey, F. Lancet (1986) [Pubmed]
  3. Furazolidone-induced cardiomyopathy in turkeys. Association with a relative alpha1-antitrypsin deficiency. Staley, N.A., Noren, G.R., Bandt, C.M., Sharp, H.L. Am. J. Pathol. (1978) [Pubmed]
  4. Myocardial diseases of animals. Van Vleet, J.F., Ferrans, V.J. Am. J. Pathol. (1986) [Pubmed]
  5. Nonfluid therapy and selected chemoprophylaxis of acute diarrhea. Du Pont, H.L. Am. J. Med. (1985) [Pubmed]
  6. Furazolidone-induced mood disorder during the treatment of refractory giardiasis in a patient with AIDS. Elliott, A.M., Klaus, B.D., North, D.S., Martin, H.P. Clin. Infect. Dis. (1998) [Pubmed]
  7. Contribution to the pathobiochemistry of furazolidone-induced oxidative toxicity in chickens. Sas, B. Acta Vet. Hung. (1993) [Pubmed]
  8. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Liao, R., Nascimben, L., Friedrich, J., Gwathmey, J.K., Ingwall, J.S. Circ. Res. (1996) [Pubmed]
  9. Recovery of neurofilament expression selectively in regenerating reticulospinal neurons. Jacobs, A.J., Swain, G.P., Snedeker, J.A., Pijak, D.S., Gladstone, L.J., Selzer, M.E. J. Neurosci. (1997) [Pubmed]
  10. N-[5-nitro-2-furfurylidene]-3-amino-2-oxazolidinone activation by the human intestinal cell line Caco-2 monitored through noninvasive electron spin resonance spectroscopy. Rossi, L., De Angelis, I., Pedersen, J.Z., Marchese, E., Stammati, A., Rotilio, G., Zucco, F. Mol. Pharmacol. (1996) [Pubmed]
  11. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity. Bell, C.A., Cory, M., Fairley, T.A., Hall, J.E., Tidwell, R.R. Antimicrob. Agents Chemother. (1991) [Pubmed]
  12. Efficacy of combined furazolidone and neomycin in the control of contamination in Leptospira cultures. Myers, D.M. Antimicrob. Agents Chemother. (1975) [Pubmed]
  13. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. Xiao, S.D., Liu, W.Z., Hu, P.J., Xia, D.H., Tytgat, G.N. Aliment. Pharmacol. Ther. (1999) [Pubmed]
  14. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Van Zwet, A.A., Thijs, J.C., van der Wouden, E.J., Kooy, A. Aliment. Pharmacol. Ther. (1997) [Pubmed]
  15. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Wong, W.M., Wong, B.C., Lu, H., Gu, Q., Yin, Y., Wang, W.H., Fung, F.M., Lai, K.C., Xia, H.H., Xiao, S.D., Lam, S.K. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  16. Reduced lipid peroxidation in dilated hearts of cardiomyopathic turkeys. Lax, D., Zhang, S.L., Li, Y., Williams, L., Berry, J.M., Elsperger, J., Staley, N.A., Noren, G.R., Einzig, S. Cardiovasc. Res. (1988) [Pubmed]
  17. Contrasting effects of spontaneous and induced cardiomyopathy on the nucleoproteins of turkey hearts. Limas, C.J., Einzig, S., Noren, G. Cardiovasc. Res. (1982) [Pubmed]
  18. Antibiotic resistance patterns of aerobic coryneforms and furazolidone-resistant Gram-positive cocci from the skin surface of the human axilla and fourth toe cleft. Eady, E.A., Coates, P., Ross, J.I., Ratyal, A.H., Cove, J.H. J. Antimicrob. Chemother. (2000) [Pubmed]
  19. Colonization of broiler chickens by waterborne Campylobacter jejuni. Pearson, A.D., Greenwood, M., Healing, T.D., Rollins, D., Shahamat, M., Donaldson, J., Colwell, R.R. Appl. Environ. Microbiol. (1993) [Pubmed]
  20. Characteristics of coagulase-negative staphylococci that help differentiate these species and other members of the family Micrococcaceae. Hébert, G.A., Crowder, C.G., Hancock, G.A., Jarvis, W.R., Thornsberry, C. J. Clin. Microbiol. (1988) [Pubmed]
  21. Myocardial myoglobin deficiency in various animal models of congestive heart failure. O'Brien, P.J., O'Grady, M., McCutcheon, L.J., Shen, H., Nowack, L., Horne, R.D., Mirsalimi, S.M., Julian, R.J., Grima, E.A., Moe, G.W. J. Mol. Cell. Cardiol. (1992) [Pubmed]
  22. Inhibition of monoamine oxidase by furazolidone in the chicken and the influence of the alimentary flora thereon. Ali, B.H., Bartlet, A.L. Br. J. Pharmacol. (1980) [Pubmed]
  23. Developmental increases in expression of neurofilament mRNA selectively in projection neurons of the lamprey CNS. Jacobs, A.J., Swain, G.P., Selzer, M.E. J. Comp. Neurol. (1996) [Pubmed]
  24. Carnitine alterations in spontaneous and drug-induced turkey congestive cardiomyopathy. Pierpont, M.E., Judd, D., Borgwardt, B., Noren, G.R., Staley, N.A., Einzig, S. Pediatr. Res. (1985) [Pubmed]
  25. Reversible interaction of a reactive intermediate derived from furazolidone with glutathione and protein. Vroomen, L.H., Berghmans, M.C., Groten, J.P., Koeman, J.H., van Bladeren, P.J. Toxicol. Appl. Pharmacol. (1988) [Pubmed]
  26. In vitro effect of tinidazole and furazolidone on metronidazole-resistant Trichomonas vaginalis. Narcisi, E.M., Secor, W.E. Antimicrob. Agents Chemother. (1996) [Pubmed]
  27. Antibiotic-resistant H. pylori infection and its treatment. Graham, D.Y., Qureshi, W.A. Curr. Pharm. Des. (2000) [Pubmed]
  28. Furazolidone-pethidine interaction in rabbits. Eltayeb, I.B., Osman, O.H. Br. J. Pharmacol. (1975) [Pubmed]
  29. Characterization of additional casein kinase I sites in the C-terminal "tail" region of chicken and rat neurofilament-M. Shaw, G., Miller, R., Wang, D.S., Tang, D., Hollander, B.A., Bennett, G.S. J. Neurochem. (1997) [Pubmed]
  30. The mutational specificity of furazolidone in the lacI gene of Escherichia coli. Bertenyi, K.K., Lambert, I.B. Mutat. Res. (1996) [Pubmed]
  31. The effect of probiotics on the genotoxicity of furazolidone. Raipulis, J., Toma, M.M., Semjonovs, P. Int. J. Food Microbiol. (2005) [Pubmed]
  32. Mutations in Helicobacter pylori porD and oorD genes may contribute to furazolidone resistance. Su, Z., Xu, H., Zhang, C., Shao, S., Li, L., Wang, H., Wang, H., Qiu, G. Croat. Med. J. (2006) [Pubmed]
  33. Detection of furazolidone in human biological fluids by high performance liquid chromatography. Valadez-Salazar, A., Guiscafre-Gallardo, H., Sanchez-Garcia, S., Muñoz, O. J. Antimicrob. Chemother. (1989) [Pubmed]
  34. Chemotherapy in giardiasis: clinical responses and in vitro drug sensitivity of human isolates in axenic culture. McIntyre, P., Boreham, P.F., Phillips, R.E., Shepherd, R.W. J. Pediatr. (1986) [Pubmed]
  35. The use of prophylactic furazolidone to control a nosocomial epidemic of multiply resistant Salmonella typhimurium in pediatric wards. Kassis, I., Dagan, R., Chipman, M., Alkan, M., Simo, A., Gorodischer, R. Pediatr. Infect. Dis. J. (1990) [Pubmed]
  36. Myofibrillar responsiveness to cAMP, PKA, and caffeine in an animal model of heart failure. Okafor, C.C., Saunders, L., Li, X., Ito, T., Dixon, M., Stepenek, A., Hajjar, R.J., Wood, J.R., Doye, A.A., Gwathmey, J.K. Biochem. Biophys. Res. Commun. (2003) [Pubmed]
WikiGenes - Universities